In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Welcome to the calm before the Covid-19 storm.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.